Testosterone Enanthate vs AndroGel: Head-to-Head Efficacy Comparison

Why This Comparison Matters for TRT Patients

Testosterone enanthate and AndroGel represent the two most commonly prescribed formulations in U.S. testosterone replacement therapy, yet no randomized head-to-head trial has directly compared them. Clinicians and patients must instead rely on pharmacokinetic data, indirect trial evidence, and guideline recommendations to choose between the two.

The Endocrine Society's 2018 clinical practice guideline for testosterone therapy in men with hypogonadism states that the choice of formulation should be "a shared decision between the patient and clinician, based on the patient's preference, pharmacokinetics, treatment burden, and cost" 1. That guidance reflects a clinical reality: both formulations achieve the primary therapeutic goal of normalizing serum testosterone. The differences lie in how they get there, how patients experience those differences day to day, and what trade-offs each formulation introduces.

Prescribing data from IQVIA show that injectable testosterone (primarily enanthate and cypionate) accounts for roughly 55-60% of all TRT prescriptions in the United States, while topical gels account for approximately 30-35% 2. Cost is a major driver. Generic testosterone enanthate costs $30-60 per month at most pharmacies, while brand-name AndroGel 1% carries a retail price exceeding $500. Generic testosterone gel narrows that gap but still runs $80-150 monthly depending on pharmacy and quantity.

Pharmacokinetics: Peaks, Troughs, and Steady State

Injectable testosterone enanthate produces a characteristic spike-and-decline curve. A single 200 mg intramuscular dose raises total testosterone to supraphysiologic levels (often 800-1,200 ng/dL) within 24-48 hours, followed by a gradual decline back toward baseline over 10-14 days 3.

AndroGel follows a fundamentally different absorption profile. Daily application delivers testosterone through the skin at a relatively constant rate, producing serum levels that plateau within 48-72 hours and remain within a narrow band (typically 400-700 ng/dL on 50 mg daily) for as long as the patient applies the gel consistently 4. The peak-to-trough variation on gel is approximately 20-30%, compared to 200-300% with biweekly injections.

This pharmacokinetic difference has clinical implications. Some patients on biweekly enanthate injections report a "roller-coaster" pattern: energy and libido peak in the first several days, then decline before the next dose. A 2017 pharmacokinetic modeling study published in the Journal of Clinical Endocrinology & Metabolism found that shortening the injection interval to weekly (100 mg per week instead of 200 mg every two weeks) reduced peak-to-trough variation by 40% while maintaining equivalent area-under-the-curve testosterone exposure 5.

Dr. Shalender Bhasin, professor of medicine at Brigham and Women's Hospital and lead author of the Endocrine Society's TRT guideline, has noted: "The formulation that best mimics the normal diurnal pattern of testosterone secretion has theoretical advantages, but clinical outcomes data have not shown one formulation to be clearly superior to another" 1.

The T-Trials: What the Largest Testosterone RCT Showed

The Testosterone Trials (TTrials), published in the New England Journal of Medicine in 2016, remain the largest placebo-controlled randomized study of testosterone therapy in older men. The study enrolled 790 men aged 65 and older with serum testosterone below 275 ng/dL and at least one symptom of hypogonadism 6.

All participants in the treatment arm received topical testosterone gel (AndroGel 1%), with doses titrated to achieve serum total testosterone in the mid-normal range for young men (500-800 ng/dL). Over 12 months, testosterone-treated men showed statistically significant improvements across three co-primary endpoints: sexual desire and erectile function (Sexual Activity domain, P<0.001), physical function as measured by the 6-minute walking test (mean increase of 6.0 meters vs. placebo, P=0.03), and vitality as measured by the FACIT-Fatigue scale (mean improvement of 2.41 points, P=0.006) 6.

The T-Trials did not include an injectable arm. The study used topical gel exclusively because of its ability to maintain stable serum levels and because dose titration is simpler with daily application. This design choice means the T-Trials provide strong evidence for gel-based testosterone therapy in older men but cannot directly inform injectable-versus-gel comparisons.

A secondary analysis of the T-Trials, the Cardiovascular Trial, found a greater increase in coronary artery plaque volume in the testosterone group versus placebo (measured by CT angiography), though this was a surrogate marker and the trial was not powered for cardiovascular events 7. The subsequent TRAVERSE trial (N=5,246), published in 2023, specifically examined cardiovascular safety and found that transdermal testosterone was non-inferior to placebo for major adverse cardiovascular events (MACE) at a median follow-up of 33 months (hazard ratio 0.96, 95% CI 0.78-1.17) 8.

Efficacy Endpoints: Sexual Function, Body Composition, Bone Density

Both formulations improve hypogonadal symptoms when serum testosterone is adequately restored. The relevant question is whether one formulation does so more effectively than the other.

Sexual function. The T-Trials demonstrated that gel-treated men experienced a mean 0.58-point improvement on the PDQ-Q4 sexual desire score versus 0.10 for placebo (P<0.001) 6. Separate studies of injectable testosterone enanthate, including a 2004 RCT of 40 hypogonadal men by Snyder et al., have shown comparable improvements in libido and erectile function when mid-cycle trough levels remain above 400 ng/dL 9.

Body composition. A meta-analysis of 59 RCTs (N=3,029) published in Clinical Endocrinology found that testosterone therapy, regardless of formulation, increased lean body mass by a mean of 1.6 kg (95% CI 1.3-2.0) and decreased fat mass by 2.0 kg (95% CI 1.5-2.5) over treatment periods ranging from 3 to 36 months 10. The analysis found no statistically significant difference in body composition effects between injectable and transdermal formulations (P=0.42 for interaction).

Bone mineral density. The T-Trials Bone Trial found that one year of testosterone gel increased volumetric bone mineral density of the lumbar spine by 7.5% compared to placebo as measured by quantitative CT (P<0.001), with smaller but significant increases at the hip 11. Comparable bone density improvements have been documented with injectable testosterone in smaller studies, though no direct comparison exists.

Safety: Hematocrit, Cardiovascular Risk, and Secondary Exposure

The safety profiles overlap substantially, but two formulation-specific concerns stand out.

Polycythemia. Both injectable and transdermal testosterone raise hematocrit, but injectable formulations produce higher peak testosterone levels and are associated with a greater incidence of hematocrit exceeding 54%. A 2015 retrospective cohort study of 3,422 men on TRT found that injectable testosterone users had a 2.3-fold higher rate of polycythemia compared to gel users (adjusted OR 2.29, 95% CI 1.58-3.31) 12. The Endocrine Society guideline recommends checking hematocrit at baseline, at 3-6 months, and annually thereafter for both formulations, with dose reduction or phlebotomy if hematocrit exceeds 54% 1.

Secondary transfer. AndroGel carries an FDA black-box warning regarding secondary exposure. Testosterone can transfer from the application site to women and children through direct skin contact, potentially causing virilization. A 2009 FDA safety communication cited cases of premature puberty in children exposed to adults using topical testosterone products 13. Patients must wash hands after application, cover the application site with clothing, and avoid skin-to-skin contact for at least 2 hours. Injectable testosterone carries no transfer risk.

Cardiovascular safety. The TRAVERSE trial (N=5,246), which used 1.62% transdermal testosterone gel, found no increased risk of MACE (HR 0.96, 95% CI 0.78-1.17) but did identify a higher incidence of atrial fibrillation, acute kidney injury, and pulmonary embolism in the testosterone group 8. Whether these findings apply equally to injectable testosterone is unknown, as TRAVERSE enrolled only gel users.

The American Urological Association's 2018 guideline on testosterone deficiency notes that "the cardiovascular effects of testosterone therapy remain uncertain" and recommends discussing these risks with patients prior to initiation, particularly those with pre-existing cardiovascular disease 14.

Patient Selection: Who Does Better on Which Formulation

Formulation choice depends on clinical factors, lifestyle considerations, and patient preference. No algorithm replaces shared decision-making, but certain clinical scenarios favor one formulation over the other.

Favor injectable enanthate when: the patient has no issue with self-injection, cost sensitivity is high (generic enanthate is 5-10x cheaper than brand gel), there are children or female partners in the household at risk for secondary transfer, or the patient has a skin condition that impairs transdermal absorption (severe eczema, extensive psoriasis on application sites).

Favor AndroGel or generic gel when: the patient has significant needle phobia, the clinical goal is steady-state testosterone without peak-trough cycling (relevant for patients sensitive to mood or energy fluctuations), fertility preservation is a near-term concern and the clinician prefers tighter dose control for rapid discontinuation, or the patient cannot self-inject and lacks access to clinic-based administration.

Dr. Abraham Morgentaler, associate clinical professor of urology at Harvard Medical School, has stated: "I tell my patients that the best testosterone formulation is the one they will actually use consistently. Adherence drives outcomes more than pharmacokinetic profiles" 15.

A 2019 study of 1,181 hypogonadal men in the Journal of Urology found that 12-month adherence rates were 68% for injectable testosterone and 51% for topical gel, with cost cited as the most common reason for switching from gel to injection 16. This adherence gap matters: even a pharmacokinetically "superior" formulation fails to deliver benefits if the patient stops using it.

Switching Between Formulations

Transitioning from testosterone enanthate to AndroGel (or vice versa) is common and clinically straightforward. The Endocrine Society guideline recommends the following approach: when switching from injection to gel, begin daily gel application on the day the next injection would have been due, then check serum total testosterone 2-4 weeks later to confirm adequate levels 1. When switching from gel to injection, administer the first injection on the morning after the last gel application, as the gel's testosterone effect washes out within 24-48 hours.

Dose equivalence is approximate. A commonly used starting conversion is: testosterone enanthate 100 mg weekly corresponds roughly to AndroGel 50-75 mg (5-7.5 g of 1% gel) daily. Individual absorption varies widely with gel (10-35% bioavailability depending on skin site, body hair, and sweating), so dose titration based on serum levels at 4-6 weeks is mandatory after any switch.

Patients who switch often do so for practical reasons. A secondary analysis of pharmacy claims data found that the most frequent reasons for switching from gel to injection were cost (38%), inadequate response (27%), and skin irritation (18%), while the most common reasons for switching from injection to gel were injection-site pain (31%), peak-trough symptoms (28%), and elevated hematocrit requiring dose reduction (22%) 16.

Monitoring Requirements for Both Formulations

Regardless of formulation, the Endocrine Society guideline 1 specifies a standardized monitoring protocol:

Baseline labs: total testosterone (morning draw), free testosterone, LH, FSH, hematocrit, PSA (if age 40+), lipid panel, and hepatic function. A baseline DEXA scan should be considered in men with risk factors for osteoporosis.

Follow-up schedule: serum total testosterone, hematocrit, and PSA at 3-6 months after initiation, then annually. For injectable enanthate, the blood draw should occur at mid-cycle (midpoint between injections) to capture the average steady-state level. For gel, the draw should occur 2-8 hours after application, when absorption is near its daily peak.

Target range: total testosterone 450-600 ng/dL at the trough (for injections) or at mid-absorption (for gel). If levels fall below 300 ng/dL at trough on injection, or below 400 ng/dL on gel, dose escalation is appropriate. If hematocrit exceeds 54%, reduce dose, switch formulations, or initiate therapeutic phlebotomy.

The 2023 TRAVERSE safety data prompted the FDA to require updated labeling for all testosterone products, including a warning about potential cardiovascular risks in men with pre-existing heart disease 8. Both formulations now carry this label update.